临沧外阴长个痘痘怎么办(临沧阴道有时少量出血什么问题) (今日更新中)

BEIJING, Jan. 24 (Xinhua) -- China's top economic planner said Monday that price supervision and control measures have achieved steady progress with 2010's Consumer Price Index, slightly exceeding the target ceiling by 0.3 percentage points to hit 3.3 percent.To rein in soaring commodities prices, joint efforts have been made to manage inflation expectations, promote production, ensure supplies and strengthen price supervision in 2010, said the National Development and Reform Commission (NDRC) in an online statement.Prices of necessities accelerating during the second half of 2010 have been contained with vegetable prices down 9.4 percent in December from the previous month last year, it said.Further, prices of edible vegetable, pork, egg, sugar,liquefied petroleum gas and clothing also decreased significantly in December month on month, the statement said.To cope with rising prices beginning in July 2010, especially prices of basic supplies, the central government promptly introduced joint inter-ministerial meetings to discuss price controls among 17 ministries and ordered local governments to establish the same mechanism, it noted.Local governments have worked on improving agricultural facilities, especially in south China's Hainan province, to increase vegetables supplies for northern cities over the past year, the statement said.The statement forecasts that vegetable planting areas in 2010's autumn and winter will increase 530,000 hectares year on year, sending output to 337 million tonnes.To ensure production and supply, departments have worked to reduce fertilizer exports and promote links between production areas and purchasing areas, it added.Further, relevant authorities also took measures to stabilize prices of electricity and coal, and to ensure smooth transportation of agricultural produce.Authorities also granted temporary subsidies and raised basic wages and minimum living subsidies for urban and rural residents to guarantee people's daily life.

CANBERRA, May 27 (Xinhua) -- An Australian student has discovered a part of the universe that astrophysicists have spent decades trying to find, Australia's Monash University on Friday confirmed in a statement.Astrophysicists have long thought the universe has a greater mass than is visible in the planets, but they had no way of proving it is there.Undergraduate student Amelia Fraser-McKelvie, 22, was on a summer internship at Monash University to learn more about astrophysics, when she managed to solve one of the big mysteries of science.Fraser-McKelvie, an aerospace engineering student, conducted a targeted X-ray search for the matter and found evidence of it within three months.Her tutor, Kevin Pimbblet, said the discovery is significant."We've been looking for this ordinary matter for a couple of decades," he said in a statement on Friday."It's been published in one of the most prestigious journals in the world, so astronomers all over the world will be able to read this article."Scientists had thought the matter would have a temperature of about 1 million degrees Celsius, 1.8 million degrees Fahrenheit, and should therefore be observable at X-ray wavelengths.Amelia Fraser-McKelvie's discovery has proved that prediction is correct, Pimbblet said.The trio published a research paper on the missing mass in one of the world's oldest and most prestigious scientific journals, Monthly Notices of the Royal Astronomical Society.He said the discovery could change the way telescopes are built.

SAN FRANCISCO, April 5 (Xinhua) -- Apple Inc.'s iPad 2 has topped the ratings by Consumer Reports, an influential U.S. magazine for product reviews, in the latest tests of the 10 most- promising tablet computers.According to the ratings released on Tuesday, the Apple iPad 2 with Wi-Fi plus 3G (32G), which is priced at 730 U.S. dollars, topped the ratings, scoring "excellent" in nearly every category.Besides several models from Apple, other brands tested include Archos, Dell, Motorola, Samsung and Viewsonic. Each tablet was evaluated on 17 criteria, including touch-screen responsiveness, versatility, portability, screen glare and ease of use."So far, Apple is leading the tablet market in both quality and price, which is unusual for a company whose products are usually premium priced," Paul Reynolds, electronics editor at Consumer Reports, said in a statement.The Motorola Xoom, whose price is 800 dollars, stood out as the iPad 2's main rival. It boasts several features that the iPad lacks, including a built-in memory card reader and support for the Flash videos.The first-generation iPad, priced at 580 dollars, also outscored many of the other models tested but tied with the Motorola Xoom, according to tests by Consumer Reports.

WASHINGTON, April 11 (Xinhua) -- In the first clinical trial of gene therapy for treatment of intractable pain, U.S. researchers from the University of Michigan's Department of Neurology observed that the treatment appears to be able to provide substantial pain relief.In a study published online in the Annals of Neurology and seen on Monday, the researchers showed that the novel agent NP2 is safe and well-tolerated. In addition, measures of pain in the treated patients suggested that NP2 may provide a substantial analgesic effect.NP2 is a gene transfer vector that expresses the naturally- occurring opioid peptide enkephalin. In preclinical work in animals, David Fink, chair of the Department of Neurology, and his coworkers had demonstrated that injection of NP2 into the skin reduces pain in models of pain caused by nerve damage, inflammation or cancer.In the clinical trial, 10 patients with unrelenting pain caused by cancer were injected with the gene transfer agent in the area of skin related to the location of pain."The concept underlying this therapeutic approach is that injection of NP2 into the skin results in uptake into the nervous system and the production and release of a pain-relieving chemical in a controlled site in the pain pathway," says Fink. "In the study, patients who received the low dose of vector showed little reduction in pain; patients receiving the higher doses showed a greater than 80 percent reduction in pain over the course of four weeks following treatment."Fink's laboratory has been working on the use of modified herpes simplex virus-based vectors that are taken up by sensory nerves following skin injection to develop therapies for diseases of the nervous system for more than 20 years. Patents related to this technology have been exclusively licensed by Diamyd Medical, a publicly-traded Swedish biotechnology company that sponsored the trial, and the human-grade vector NP2 was produced by Diamyd, Inc, the U.S. subsidiary of Diamyd Medical.A phase 2 trial to compare NP2 to a placebo control has already been initiated under sponsorship from Diamyd.

来源：资阳报